ExelixisEXEL
EXEL
About: Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Employees: 1,147
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 14 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
166% more first-time investments, than exits
New positions opened: 117 | Existing positions closed: 44
31% more capital invested
Capital invested by funds: $6.37B [Q3] → $8.33B (+$1.96B) [Q4]
29% more funds holding in top 10
Funds holding in top 10: 7 [Q3] → 9 (+2) [Q4]
18% more call options, than puts
Call options by funds: $58.6M | Put options by funds: $49.7M
15% more funds holding
Funds holding: 447 [Q3] → 512 (+65) [Q4]
1.47% more ownership
Funds ownership: 86.06% [Q3] → 87.53% (+1.47%) [Q4]
4% more repeat investments, than reductions
Existing positions increased: 172 | Existing positions reduced: 165
Research analyst outlook
14 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$29
20%
downside
Avg. target
$38
4%
upside
High target
$45
24%
upside
14 analyst ratings
9 positive
64%
5 neutral
36%
0 negative
0%
JMP Securities Silvan Tuerkcan 20% 1-year accuracy 10 / 51 met price target | 13%upside $41 | Market Outperform Reiterated | 17 Apr 2025 |
HC Wainwright & Co. Robert Burns 16% 1-year accuracy 28 / 172 met price target | 11%upside $40 | Buy Reiterated | 27 Mar 2025 |
RBC Capital Gregory Renza 16% 1-year accuracy 12 / 73 met price target | 11%upside $40 | Outperform Maintained | 13 Mar 2025 |
Wells Fargo Derek Archila 45% 1-year accuracy 14 / 31 met price target | 1%downside $36 | Equal-Weight Downgraded | 24 Feb 2025 |
Barclays Peter Lawson 5% 1-year accuracy 1 / 21 met price target | 20%downside $29 | Equal-Weight Maintained | 13 Feb 2025 |
Financial journalist opinion
Based on 11 articles about EXEL published over the past 30 days
Positive
Zacks Investment Research
4 days ago
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Positive
Zacks Investment Research
1 week ago
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Positive
Zacks Investment Research
1 week ago
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Positive
The Motley Fool
2 weeks ago
The Smartest Biotech Stocks to Buy With $50
One of the great things about equity markets is that you don't need a fortune to get started. Though strong companies that perform well tend to attract plenty of attention that bids up their share prices, it's possible to buy shares of quality stocks with $50 -- or less.
Positive
Zacks Investment Research
3 weeks ago
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors
Exelixis obtains FDA nod for label expansion of lead drug Cabometyx for neuroendocrine tumors.
Positive
Zacks Investment Research
3 weeks ago
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?
EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and efforts to improve shareholder value. However, the recent rally might limit further gains for shareholders.
Positive
Zacks Investment Research
3 weeks ago
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Neutral
Business Wire
3 weeks ago
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET); and 2) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or.
Neutral
Business Wire
3 weeks ago
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that preclinical data will be presented for four pipeline molecules at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30 in Chicago, IL. “We are excited to share preclinical data from four of our pipeline molecules that constitute the next phase in our commitment to the discovery and development of innovative cancer treatments,” said Dana T. Aftab, Ph.D., Executive Vice.
Positive
Investors Business Daily
3 weeks ago
Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally
Biotech leader Exelixis stock is attempting to regain a recent buy point during Monday's stock market rally. The post Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally appeared first on Investor's Business Daily.
Charts implemented using Lightweight Charts™